BPB Reports

Paper Details

BPB Reports
Vol. 5 No. 6 p.147-153 2022
Regular Article
Effects of Keishi-Bukuryo-gan-ka-Yokuinin on Rosacea Model Mice
  • Akinobu Gotoh (Cell and Gene Therapy, Hyogo Medical University / Department of Education for Medical Research Base, Hyogo Medical University / gotoh@hyo-med.ac.jp)
Natsu Watanabe 1) 2) , Wataru Matsunaga 1) 3) , Akinobu Gotoh 1) 4)
1) Cell and Gene Therapy, Hyogo Medical University , 2) Watanabe Skin and Plastic Surgery Clinic , 3) Joint-use Research Facilities, Hyogo Medical University , 4) Department of Education for Medical Research Base, Hyogo Medical University
Received: October 31, 2022;   Accepted: November 29, 2022;   Released: December 15, 2022
Keywords: rosacea, Keishi-Bukuryo-gan-ka-Yokuinin, velocity of capillaries, gut microbiota

Rosacea is an intractable skin disease and no effective treatment has been established, but there are cases of improvement with Kampo medicine. In this study, the efficacy of Keishi-Bukukryo-gan-ka-Yokuinin (KBY) in ameliorating the symptoms of rosacea was investigated in a steroid-induced rosacea mouse model. The mice were fed a KBY-containing diet for 28 d, after application of clobetasol propionate for 10 d; thereafter, the velocity of capillary blood flow, area of the skin purpura, histopathologic features, and gut microbiota were analyzed. The KBY-fed mice showed remarkable recovery in the capillary blood flow velocity and purpura area, as well as restoration of the epidermis features. Furthermore, gut microbiome analysis showed the enhancement of Lactobacillus population in the KBY-fed mice. The KBY-induced improvement of circulatory disturbances in skin might contribute to the alleviation of telangiectasia and erythema. Lactobacillus may be involved in alleviating the rosacea-like symptoms in association with KBY; however, this association should be investigated further by using other analysis methods. Our results provide evidence of the effectiveness of KBY in improving the pathology of rosacea.